Announcing Fungible Storage Cluster with Support for VMware vSphere
7.6.2022 16:01:00 EEST | Business Wire | Press release
Fungible Inc., the dynamic composable infrastructure company, today announced a new release of Fungible Storage Cluster® (FSC) 4.1, providing support for VMware vSphere® environments requiring high-performance.
Virtual machines provide unparalleled flexibility in managing complex and changing compute environments. Workloads running in virtualized environments can have varied storage requirements. For demanding workloads, Fungible’s high-performance all-flash array based on NVMe/TCP is now certified for vSphere and available for VMware virtualized environments. The latest release (4.1) will now enable customers to experience the superior manageability of vSphere combined with the high performance of Fungible’s Storage Cluster.
"NVMe/TCP enables vSphere customers to accelerate their storage performance while leveraging existing investments and lowering complexity,” said Marc Fleischmann, Cloud CTO, VMware, “Through collaboration with innovative companies such as Fungible, VMware continues to build a world-class ecosystem of technology partners that offer our customers flexibility and choice to meet their business requirements.”
Customers can plug FSC storage into their ESXi servers with NVMe/TCP and get what appears to be local storage. The resulting performance is nearly identical to local storage even though it is a shared resource providing economic benefits to match the performance benefits.
“VMware vSphere is the virtualization infrastructure of choice for a variety of mission-critical, performance-sensitive workloads in the data center,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies at IDC. “As IT organizations deploy more workloads that require accelerated compute and storage, the use of composable, disaggregated infrastructure (CDI) like that available from Fungible will be deployed more often to enable the more efficient use of these types of resources in VMware environments. IDC expects that the CDI market overall will top $4.8 billion by 2025.”
“VMware has long led the drive to improve flexibility and utilization of data center infrastructure. Now with the latest release of our vSphere certified Fungible Storage Cluster, VMware users can further enhance their ability to tune demanding workloads to get the utmost performance and flexibility,” said Pradeep Sindhu, Co-Founder and CDO of Fungible. “Trade-offs of flexibility versus performance are no longer required. Pairing VMware with NVMe/TCP for storage access with our DPU-powered Storage Cluster allows VMware customers to address the performance requirements of today's modern applications.”
With FSC, vSphere users may also see storage cost savings since FSC’s erasure coding provides robust data protection which can be less expensive than traditional RF1 or RF2 replication. Additionally, Fungible’s composable data infrastructure provides flexibility to compose storage to meet current needs and recompose it to adapt to changing needs providing outstanding investment protection.
To learn more about the new FSC 4.1 and the VMware vSphere certification and how you can get more value and performance from your VMware vSphere resources click here or contact sales@fungible.com.
About Fungible:
Silicon Valley-based Fungible, the world’s premier dynamic composable infrastructure company, creates solutions to cloudify the world’s data centers by utilizing the Fungible DPU™ to connect CPUs, GPUs, and storage via NVMe/TCP over standard IP/Ethernet networks. Fungible aims to revolutionize the performance, economics, reliability and security of scale-out data centers. Visit Fungible to learn more. Follow us on Twitter and LinkedIn.
Fungible and Fungible FSC are registered trademarks of Fungible, Inc. VMware and vSphere are registered trademarks or trademarks of VMware, Inc. in the United States, and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005155/en/
Contact information
Jennifer Bell
Fungible, Inc.
(669) 292-5522
press@fungible.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
